BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. - Monday, 26. February 2024 AETOSWire Print
Recommendation based on results of three Phase 3 clinical trials demonstrating benefit of tislelizumab as a first- and second-line treatment for patients with NSCLC
(BUSINESS WIRE)--BeiGene, Ltd. (NAS…